Severe thrombocytopenia after hepatitis B vaccine in an infant from Turkey

Area of Science:

• Pediatric immunology
• Vaccine safety research
• Hematology

Background:

• Recombinant hepatitis B vaccine, widely used since 1991, has a generally favorable safety profile.
• Adverse events following immunization are infrequent.
• Hepatitis B vaccination is a critical public health intervention for preventing chronic infection.

Observation:

• An infant developed severe thrombocytopenia (low platelet count) after receiving the second dose of hepatitis B vaccine.
• The infant presented with an extremely low platelet count, reportedly the lowest documented in medical literature.
• This case involved a very young patient, making the observation particularly noteworthy.

Findings:

• The infant experienced severe thrombocytopenia, a rare but serious potential side effect of the hepatitis B vaccine.
• Treatment with intravenous immunoglobulin (IVIG) was administered.
• Despite the severity of the thrombocytopenia, the infant achieved a full recovery without any bleeding complications.

Implications:

• This case underscores the importance of monitoring for rare adverse events following vaccination, even in widely used vaccines.
• It highlights the potential for severe thrombocytopenia in infants post-hepatitis B vaccination.
• The successful treatment with IVIG suggests a viable therapeutic option for managing vaccine-induced thrombocytopenia.